EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies

Menglan Pang, Holly M Brothers, John O'Gorman, Jennifer Murphy, Yuval Zabar, Tyler Lasky, Changyu Shen, Ivana Rubino, David Knopman

Alzheimer's & Dementia · 2026-10 · 22 (10)

DOI: 10.1002/alz.71758 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.10.2026. Verfasst von Menglan Pang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biogen Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Alzheimer Disease, Amyloid beta-Peptides, Amyloid. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Anti‐amyloid antibody clinical trials with a high proportion of participants reaching treatment‐related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the double‐blind period was likewise associated with clinical benefit. METHODS We pooled ENGAGE and EMERGE (E/E) aducanumab‐treated participants in the amyloid positron emission tomography substudy who continued into the long‐term extension ≤ 134 weeks (continuously treated population) and/or returned to the EMBARK redosing study 0.7 to 2.5 years after termination of E/E (treatment gap population). Clinical outcomes were stratified by week 78 TRAC status. RESULTS TRAC participants had less clinical decline at week 78, week 134, and EMBARK baseline than non‐TRAC participants. Post‐TRAC, clinical decline was heterogeneous; approximately two thirds of TRAC participants had annualized decline of < 1 point on Clinical Dementia Rating Sum of Boxes. DISCUSSION In these exploratory analyses, week 78 TRAC status was associated with better clinical outcomes. CLINICAL TRIAL REGISTRATION NCT02484547, NCT02477800, NCT04241068

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAlzheimer DiseaseAmyloid beta-PeptidesAmyloidHumansDouble-Blind MethodFemaleMaleTreatment OutcomePositron-Emission TomographyAgedLongitudinal Studies

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid negativeanti‐amyloid antibodyanti‐amyloid therapymild cognitive impairmenttreatment‐related amyloid clearance

Substanzen

Antibodies, Monoclonal, HumanizedaducanumabAmyloid beta-PeptidesAmyloid

Autor:innen und Institutionen

  • Biogen Inc., Cambridge, Massachusetts, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • Biogen

Zitieren

APA

Pang, M., Brothers, H. M., O'Gorman, J., Murphy, J., Zabar, Y., Lasky, T., Shen, C., Rubino, I., & Knopman, D. (2026). Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71758

Vancouver

Pang M, Brothers HM, O'Gorman J, Murphy J, Zabar Y, Lasky T, et al. Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71758

BibTeX
@article{Pang2026,
  author = {Pang, Menglan and Brothers, Holly M and O'Gorman, John and Murphy, Jennifer and Zabar, Yuval and Lasky, Tyler and Shen, Changyu and Rubino, Ivana and Knopman, David},
  title = {Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {10},
  doi = {10.1002/alz.71758}
}
Kostenlos starten →